Deals in Depth: March 2010
Executive SummaryGSK penned a $563 million deal with Cellzome for rights to the latter's epigenetics platform. Leading M&A was Teva's $4.5 billion bid for ratiopharm. Biopharma financing dollars rebounded, with notable private transactions including Archimedes's $100 million venture financing, and a $75 million PIPE that Lexicon did concurrent with a $111 million follow-on. Mindray's $151 million FOPO was responsible for over half of all device dollars.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.